Topical use of antifibrinolytic agent to reduce postoperative bleeding after coronary artery bypass surgery;Uso tópico de agente antifibrinolítico na redução do sangramento após revascularização cirúrgica do miocárdio

Brazilian Journal of Cardiovascular Surgery

Volumn 24, Issue 3, 2009, Pages 341-345

  Breda, João Roberto ^a   Gurian, Danilo Bortoloto ^a   Breda, Ana Silvia Castaldi Ragognetti ^a   Meneghine, Adriano ^a   Freitas, Andréa Cristina de Oliveira ^a   de Matos, Leandro Luongo ^a   de Abreu, Luiz Carlos ^a   Pires, Adilson Casemiro ^a  

^a NONE

Author keywords

Antifibrinolytic agents; Coronary artery bypass; Hemorrhage

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT;

ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; UTILIZATION REVIEW;

6-AMINOCAPROIC ACID; ADMINISTRATION, TOPICAL; ANTIFIBRINOLYTIC AGENTS; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE;

EID: 72649106166     PISSN: 01027638     EISSN: 16789741     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briët T, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999; 54(9194):1940-7.
2. Tatar H, Ciçek S, Demirkilic U, Ozal E, Süer H, Oztürk O, et al. Topical use of aprotinin in open heart operations. Ann Thorac Surg. 1993; 55(3):659-61.
3. O'Regan DJ, Giannopoulos N, Mediratta N, Kendall SW, Forni A, Pillai R, et al. Topical aprotinin in cardiac operations. Ann Thorac Surg. 1994;58(3): 778-81.
4. Hanif M, Nourei SM, Dunning J. Does the use of topical tranexamic acid in cardiac surgery reduce the incidence of post-operative mediatinal bleeding? Interact Cardiovasc Thorac Surg. 2004;3(4): 603-5.
5. De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, et al. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000;119(3):575-80.
6. Baric D, Biocina B, Unic D, Sutlic Z, Rudez I, Vrca VB, et al. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Eur J Cardiothorac Surg. 2007;31(3): 366-71.
7. Ciçek S, Tatar H, Demirkiliç U, Kuralay E. Topical use of aprotinin in cardiac surgery. J Thorac Cardiovasc Surg. 1995;110(2): 568-9.
8. Souza HJB, Moitinho RF. Estratégias para redução do uso de hemoderivados em cirurgia cardiovascular. Rev Bras Cir Cardiovasc. 2008; 23(1): 53-59.
9. Mangano DT, Tudor IC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006; 354(4):353-65.
10. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. 2006;46: 327-38.
11. nd, Haan CK, Hoyston BD, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007; 83(5 Supp): S27-86.
12. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. Bart Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008; 358(22): 2319-31.
13. Cicek S, Theodoro DA. Topical aprotinin in cardiac operations: a note of caution. Ann Thorac Surg. 1996; 61(3): 1039-40.